Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

ABSTRACT: Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the trial is to evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and tolerability.

DISEASE(S): Metastatic Colorectal Cancer,Advanced Metastatic Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2272605 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

Project description:The RANGE study (NCT02426125) evaluated ramucirumab (an anti-VEGFR2 monoclonal antibody) in patients with platinum-refractory advanced urothelial carcinoma (UC). Here, we use programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) and transcriptome analysis to evaluate the association of immune and angiogenesis pathways, and molecular subtypes, with overall survival (OS) in UC. Higher PD-L1 IHC and immune pathway scores, but not angiogenesis scores, are associated with greater ramucirumab OS benefit. Additionally, Basal subtypes, which have higher PD-L1 IHC and immune/angiogenesis pathway scores, show greater ramucirumab OS benefit compared to Luminal subtypes, which have relatively lower scores. Multivariable analysis suggest patients from East Asia as having lower immune/angiogenesis signature scores, which correlates with decreased ramucirumab OS benefit. Our data highlight the utility of multiple biomarkers including PD-L1, molecular subtype, and immune phenotype in identifying patients with UC who might derive the greatest benefit from treatment with ramucirumab. Please note that the RANGE clinical trial data generated in this study have been deposited at www.vivli.org. RANGE clinical trial data are available under restricted access to protect patient privacy, and access can be obtained by submitting a request. For details on submitting a request, see the instructions provided at www.vivli.org. For specific study details, see here: https://search.vivli.org/?search=NCT02426125.

2022-03-14 | GSE198269 | GEO

Gold nanorod based delivery system could bring about superior therapy effect of Ramucirumab through direct cytotoxicity to cancer cell mediated by differential regulation of phagocytosis in gastric cancer cell

Project description:Gastric Cancer (GC) is one of the most serious cancers with high incidence and mortality all over the world. Chemotherapy hadn’t led to desirable effect and targeted therapy brings about a new stage to cancer treatment. Ramucirumab is the first FDA-approved monotherapy for advanced gastric cancer. It is well known that gold nanorod, a nontoxic biocompatible nanomaterial, is an especially promising candidate for cancer theranostic. In this study, Ramucirumab (Ab) were first modified by gold nanoparticles to enhance uptake efficiency. The simple Nano-delivery system had taken perfect aggregation effect in vivo even better than 5-fold Ab treatment. Gold nanomaterials, especially gold nanorod (AuNR), could induce direct cytotoxic effect to cancer cell in the presence of Ab, while Ab or gold nanoparticle themselves couldn’t lead to such direct killing effect even at an extremely high concentration. Transcriptomic and proteomic analyses revealed the mechanism of this direct cytotoxicity.

2021-08-06 | GSE181369 | GEO

Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine(RAINCLOUD)

Project description:Interventions: FOLFIRI+Ramucirumab (5-FU(bolus): 400mg/m2 on day1, 5-FU(ci): 2,400mg/m2 on day1-3 (46hr), l-LV: 200mg/m2 on day1, CPT-11: 180*mg/m2 on day1, Ramucirumab: 8mg/kg on day1) *Allow dose level -1 (150mg/m2) Primary outcome(s): Progression-Free Survival (PFS) Study Design: Single arm Non-randomized

| 2643874 | ecrin-mdr-crc

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

Project description:Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

| PRJNA814304 | ENA

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Project description:The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.

| 2213121 | ecrin-mdr-crc

Phase II study of FOLFIRI+Ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy (RAINCLOUD).RAINCLOUD-TR.

Project description:Interventions: FOLFIRI+Ramucirumab (5-FU(bolus): 400mg/m2 on day1, 5-FU(ci): 2,400mg/m2 on day1-3 (46hr), l-LV: 200mg/m2 on day1, CPT-11: 180mg/m2 on day1, Ramucirumab: 8mg/kg on day1) *Allow dose level -1 (150mg/m2) RAINCLOUD-TR Collecting blood 12mL at the time of before RAINCLOUD protocol treatment, and PD. Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), no treatment control/standard of care control, parallel assignment, treatment purpose

| 2615323 | ecrin-mdr-crc

Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial.

Project description: Not available

| S-EPMC12082102 | biostudies-literature

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Project description: Not available

| S-EPMC6700046 | biostudies-literature

Neoadjuvant talimogene laherparepvec plus surgery vs surgery alone for resectable stage IIIB-IVM1a melanoma

Project description:This study was intended to describe transcriptional changes after TVEC treatment among immune related genes. Tumor gene expression analysis (nanostring, pan cancer immmune profiling panel) was performed to evaluate tumor inflammation status at baseline (in TVEC and control arms) and after treatment with TVEC. Objectives aimed to improve understanding of TVEC therapeutic mechanism of action, included assessment of baseline tumor inflammation status and assessment of change in tumor inflammation status.

2021-09-01 | GSE182162 | GEO

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

Project description:To investigate the effects of the I/IIb HDAC inhibitor, Purinostat Mesylate (PM, also called HL13) on gene expression in multiple myeloma. The MM.1S cells were treated with Ctrl (DMSO) or HL13 (5nM) for 24 hours. Then the cells were collected and total RNA were isolation by Trizol. The expression profiling by array generated following the recommended protocol of Affymetrix GeneChip Human Transcriptome Array 2.0. To investigate the effects of the I/IIb HDAC inhibitor, Purinostat Mesylate (PM, also called HL13) on gene expression in multiple myeloma. The MM.1S cells were treated with Ctrl (DMSO) or HL13 (5nM) for 24 hours. Then the cells were collected and total RNA were isolation by Trizol. The expression profiling by array generated following the recommended protocol of Affymetrix GeneChip Human Transcriptome Array 2.0.

2025-07-01 | GSE296480 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data